Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 26;40(24):3294-3297.
doi: 10.1016/j.vaccine.2022.02.014. Epub 2022 Feb 9.

Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study

Stuti Pramod  1 , Dhanajayan Govindan  1 , Premkumar Ramasubramani  1 , Sitanshu Sekhar Kar  2 , Rakesh Aggarwal  1 ; JIPMER vaccine effectiveness study group  1
Collaborators, Affiliations

Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study

Stuti Pramod et al. Vaccine. .

Abstract

Introduction: This study aimed at assessing the vaccine effectiveness (VE) of Covishield, which is identical to AstraZeneca vaccine, in preventing laboratory-confirmed Covid-19.

Methods: Using test-negative case-control design, information on vaccination status of cases with Covid-19 among healthcare workers in our institution in Puducherry, India, and an equal number of controls matched for age and date of testing, was obtained. The groups were compared using multivariable conditional logistic regression to calculate odds ratios (OR). VE was calculated as 100*(1-adjusted odds ratio)%.

Results: Using data from 360 case-control pairs, VE of one dose and of two doses, in providing protection against Covid-19 was 49% (95% CI: 17%-68%) and 54% (27%-71%), respectively. Among cases with moderately severe disease that required oxygen therapy, VE following any number of vaccine doses was 95% (44%-100%).

Conclusion: Covishield vaccine protected significantly against Covid-19, with a higher protection rate against severe forms of disease.

Keywords: Covishield; Test-negative design; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Ministry of Health and Family Welfare, Government of India. COVID-19 vaccines operational guidelines. Updated December 28, 2020. [Internet]. [cited 2021 Jul 14]. Available from: https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter...
    1. World Health Organization. 2021. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). Available from: https://apps.who.int/iris/rest/bitstreams/1343289/retrieve. Last accessed 16 July 2021.
    1. Ministry of Health and Family Welfare, Government of India. CoWIN Dashboard [Internet]. [cited 2021 July 16]. Available from: https://dashboard.cowin.gov.in/
    1. Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. - PMC - PubMed
    1. Hacisuleyman E., Hale C., Saito Y., Blachere N.E., Bergh M., Conlon E.G., et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–2218. doi: 10.1056/NEJMoa2105000. - DOI - PMC - PubMed